Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Commercials Clear all
Completed Phase 2 Interventional Results available

Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study

NCT03879408
View directory record Official record
Conditions
Pain
Interventions
440 mg naproxen sodium with 1000 mg acetaminophen, 220 mg naproxen sodium with 650 mg acetaminophen, 10 mg hydrocodone + 650 mg acetaminophen, 440 mg naproxen sodium, Placebo tablet
Drug
Lead sponsor
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
Industry
Eligibility
17 Years to 50 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naproxen Sodium ER Pharmacokinetic Study

NCT00818415
View directory record Official record
Conditions
Pain
Interventions
Naproxen sodium ER (BAYH6689), Commercial Naproxen (Aleve, BAYH6689)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Sep 9, 2026, 7:20 PM EDT
Completed No phase listed Observational

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

NCT01862367
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
7
States / cities
Orange, California • Tampa, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2019 · Synced Sep 9, 2026, 7:20 PM EDT
Terminated Phase 1 Interventional

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

NCT00958022
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LBH589 and carboplatin with etoposide
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy Study 2

NCT00780286
View directory record Official record
Conditions
Healthy Subjects
Interventions
Polymer based lubricating liquid, Moi-Stir
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Trial to Reduce Sitting Time in Postmenopausal Latina Women at Increased Risk for Heart Disease

NCT02905929
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
ActivPAL inclinometer, Phone counseling call: Breaking up sitting time, In-person counseling: Breaking up sitting time, Phone counseling call: Healthy living, Tools to prompt standing, In-person counseling: Healthy living
Device · Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
55 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
2
States / cities
Chula Vista, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 9, 2026, 7:20 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Alcoholic Liver Disease and the Gut Microbiome

NCT05007470
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholic Liver Disease, Microbiome
Interventions
VSL #3 112.5 Capsule, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Not applicable Interventional Results available

InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study

NCT04016324
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
Interventions
InterStim Basic Evaluation lead and foramen needle
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
St. Petersburg, Florida • Tampa, Florida • Plymouth, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 9, 2026, 7:20 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging

NCT04275453
View directory record Official record
Conditions
Healthy
Interventions
FDG, Ketone Drink, Ketogenetic Diet
Drug · Dietary Supplement · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Sep 9, 2026, 7:20 PM EDT
Completed No phase listed Observational

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

NCT05471830
View directory record Official record
Conditions
Prevention of Thromboembolic Events, Atrial Fibrillation
Interventions
Apixaban
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 9, 2026, 7:20 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

NCT04264442
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
Losmapimod
Drug
Lead sponsor
Fulcrum Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 9, 2026, 7:20 PM EDT
Completed No phase listed Observational

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

NCT01070836
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
35,895 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
473
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Phase 4 Interventional

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

NCT06346288
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Breast Milk Sampling, Risankizumab
Procedure · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Novel Intervention to Improve Food Insecurity Among Individuals With Opioid Use Disorder

NCT06374303
View directory record Official record
Conditions
Food Security
Interventions
NE + Meal Delivery (NE+MD) intervention
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 9, 2026, 7:20 PM EDT
Completed No phase listed Observational

Development of a Tracheal Sound Sensor

NCT05506267
View directory record Official record
Conditions
Respiratory Insufficiency, Opioid Overdose, Hypoventilation
Interventions
Trachea Sound Sensor (TSS)
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Sep 9, 2026, 7:20 PM EDT
Enrolling by invitation No phase listed Observational

CardioMEMS HF System Real-World Evidence Post-Approval Study

NCT06306573
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
CardioMEMS HF System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Timeline
2022 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 9, 2026, 7:20 PM EDT
Recruiting No phase listed Observational

Safe and Explainable AI

NCT06694181
View directory record Official record
Conditions
Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions
AI-PERSONALIZED CLINICAL DECISION SUPPORT
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 9, 2026, 7:20 PM EDT
Completed No phase listed Observational

Hypobaria and Traumatic Pneumothorax

NCT01670942
View directory record Official record
Conditions
Pneumothorax
Interventions
hypobaric chamber
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Not applicable Interventional

Feasibility and Acceptability of Switching to E-cigarettes Among Cigarette Smokers Engaged in SUD Treatment

NCT05918887
View directory record Official record
Conditions
Tobacco Dependence Caused by Cigarettes
Interventions
NJOY ACE commercial e-cigarette
Device
Lead sponsor
University of Nevada, Reno
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 9, 2026, 7:20 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

NCT04668521
View directory record Official record
Conditions
Adnexal Mass, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Hereditary Breast and Ovarian Cancer
Interventions
OVA360
Other
Lead sponsor
Aspira Women's Health
Industry
Eligibility
18 Years and older · Female only
Enrollment
215 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 9, 2026, 7:20 PM EDT
Enrolling by invitation Not applicable Interventional

VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms) Using Commercial Off-The-Shelf (COTS) Catheters

NCT06940752
View directory record Official record
Conditions
Ventricular Arrhythmia
Interventions
VINTAGE (Ventricular Intramyocardial Navigation for Tachycardia Ablation Guided by Electrograms)
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 9, 2026, 7:20 PM EDT
Terminated Phase 1 Interventional

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

NCT02235740
View directory record Official record
Conditions
Cancer
Interventions
Afuresertib, Carfilzomib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 9, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers

NCT02746926
View directory record Official record
Conditions
Healthy
Interventions
tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 9, 2026, 7:20 PM EDT